Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): ASP3652,ABX-003

            Therapeutic Area: Immunology Product Name: ASP3652

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Autobahn Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition May 11, 2021

            Details:

            Autobahn has acquired global rights to ASP3652, a novel oral peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor from Astellas Pharma. ASP3652 complements Autobahn’s brain-targeting chemistry platform, which uses FAAH-mediated prodrug conversions.